Travere Therapeutics Inc.

21.29
0.76 (3.70%)
At close: Mar 24, 2025, 3:59 PM
21.29
0.02%
After-hours: Mar 24, 2025, 04:37 PM EDT
3.70%
Bid 18.25
Market Cap 1.89B
Revenue (ttm) 248.98M
Net Income (ttm) -343.35M
EPS (ttm) -4.07
PE Ratio (ttm) -5.23
Forward PE -104.46
Analyst Buy
Ask 21.5
Volume 952,077
Avg. Volume (20D) 1,798,983.4
Open 20.81
Previous Close 20.53
Day's Range 20.48 - 21.35
52-Week Range 5.12 - 25.29
Beta 0.75

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzy...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2012
Employees 385
Stock Exchange NASDAQ
Ticker Symbol TVTX
Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 50.34% from the latest price.

Stock Forecasts

Next Earnings Release

Travere Therapeutics Inc. is scheduled to release its earnings on May 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-6.79%
Travere Therapeutics shares are trading lower. The... Unlock content with Pro Subscription
1 month ago
+1.07%
Travere Therapeutics shares are trading lower. The company reported Q4 financial results.